Adenine receptor ligands

Simple SummaryContent extracted from patent full text and abstract with AI.

The patent describes a new class of compounds that act as ligands for adenine receptors, a type of recently discovered purinergic (P0) receptor. These compounds are specifically designed to interact with adenine receptors found in the nervous system and other tissues. The ligands and their pharmaceutical compositions can be used to modulate the function of these receptors, potentially treating or preventing diseases related to their activity. In particular, these compounds are highlighted for their potential as pain-relieving (antinociceptive) and neuroprotective agents. The patent also covers methods for synthesizing these compounds and their use in combination therapies.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of neuropathic or nociceptive pain (e.g., chronic pain, nerve damage-related pain).
• Therapy for neurodegenerative conditions such as Alzheimer's, Parkinson's, Huntington's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS).
• Acute neuroprotection in cases of stroke, traumatic brain injury, or spinal cord injury.
• Prevention or amelioration of neurological disorders related to adenine receptor dysfunction, including epilepsy and neuroinflammatory diseases.
• Ophthalmological uses for retinal diseases, optic nerve stroke, and related neuropathies.
• Development of diagnostic tracers for positron emission tomography (PET) by labeling adenine receptor ligands with radioisotopes.
• Combination therapies with other neuroprotective or pain-relief agents for enhanced efficacy.

BenefitsContent extracted from patent full text and abstract with AI.

• Novel drug target: Adenine receptors are newly identified and offer therapeutic potential distinct from existing purinergic targets.
• Selective ligand action: Compounds are engineered for high selectivity and affinity to adenine receptors, which may reduce side effects compared to less selective modulators.
• Neuroprotective effect: Potential to slow or halt neural degeneration in chronic CNS diseases.
• Effective pain management: Offers new mechanism of antinociceptive action, giving alternatives to opioid or NSAID-based pain relief.
• Good drug-like properties: Improved synthetic methods enable higher yields, water solubility, and oral bioavailability, making formulation and administration easier.
• Potential for personalized medicine: Specific receptor targeting could lead to tailored treatments for patients with defined receptor activity profiles.
• Versatile formulation: Suitable for oral, injectable, or other pharmaceutical dosage forms, with options for sustained or immediate release.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to adenine receptor ligands useful for treating, alleviating and/or preventing diseases and disorders related to adenine receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviating, preventing and/or treating diseases and disorders, especially the use as antinociceptive or neuroprotective drugs.